Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

Phase 1

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: CKD-386 formulation 1
Drug: CKD-386 formulation 2
Drug: D326, D337 and D013

First Posted Date: 2019-04-19

Last Posted Date: 2019-04-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT03920579

Locations: 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers

Phase 1

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Harnal-D Tab.
Drug: Chong Kun Dang Tamsulosin HCl Tab.

First Posted Date: 2019-03-25

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT03887858

Locations: 🇰🇷
Bestian Hospital, Osong, Korea, Republic of

Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal

Phase 1

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Harnal-D Tab.
Drug: Chong Kun Dang Tamsulosin HCl Tab.

First Posted Date: 2019-03-25

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT03887871

Locations: 🇰🇷
Bestian Hospital, Osong, Korea, Republic of

Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: XELJANZ 5Mg Tablet
Drug: Chong Kun Dang Tofacitinib Tablet

First Posted Date: 2019-03-08

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 40

Registration Number: NCT03868072

Locations: 🇰🇷
Bestian Hospital, Osong, Korea, Republic of

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: D569 Tab.
Drug: CKD-374 5mg Tab.

First Posted Date: 2019-03-01

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03858725

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults

Phase 1

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: CKD-333, formula I
Drug: CKD-333, formula II
Drug: CKD-330, D090

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03849287

Locations: 🇰🇷
Seoul Saint Mary's Hospital, Seoul, Korea, Republic of

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-387
Drug: D635

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 20

Registration Number: NCT03849339

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults

Phase 1

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: CKD-387
Drug: D635

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03849261

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-375
Drug: D387

First Posted Date: 2019-02-21

Last Posted Date: 2019-03-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 28

Registration Number: NCT03848637

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-370
Drug: D745

First Posted Date: 2019-02-21

Last Posted Date: 2019-03-12

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 28

Registration Number: NCT03849495

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy